SAİP, P. M. Et Al. 2013. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial. BREAST , vol.22, no.5 , 628-633.

SAİP, P. M., Eralp, Y., AYDOĞMUŞ ŞEN, F., Karaca, H., ÖZKAN, M., ÇETİN, B. E., ... Benekli, M.(2013). Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial. BREAST , vol.22, no.5, 628-633.

SAİP, Pınar Et Al. "Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial," BREAST , vol.22, no.5, 628-633, 2013

SAİP, Pınar M. Et Al. "Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial." BREAST , vol.22, no.5, pp.628-633, 2013

SAİP, P. M. Et Al. (2013) . "Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial." BREAST , vol.22, no.5, pp.628-633.

@article{article, author={Pınar Mualla SAİP Et Al. }, title={Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial}, journal={BREAST}, year=2013, pages={628-633} }